Mawi DNA Technologies Receives 510(k) Clearance for iSWAB-Respiratory Tract Sample Collection Media-Extraction Less for SARS-CoV-2
Mawi DNA Technologies (Mawi DNA), a biotechnology company focusing on the development and design of innovative technologies for biosampling, announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s iSWAB-Respiratory Tract Sample Collection Media-Extraction Less™ (iSWAB-RC-EL). The iSWAB-RC-EL collection device is intended for the stabilization and inactivation of human upper respiratory and saliva bio specimens suspected of containing SARS-CoV-2, and can be used for collection, transport, and storage at ambient temperature. Specimens collected in the iSWAB-RC-EL collection device are suitable for use with legally marketed molecular diagnostic tests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230425005502/en/
(Graphic: Business Wire)
Mawi DNA developed the iSWAB-RC-EL bio sampling device for surveillance testing of COVID-19 and its variants in any clinical setting. The iSWAB-RC-EL is currently being used worldwide for population-scale sampling to mitigate the impact of COVID-19 spread, and it enables hospital and clinical lab personnel to skip the RNA extraction step in the PCR testing protocol. The biosampling device also offers a non-toxic formulation that inactivates viruses to decrease potential spread and exposure, especially among lab personnel processing these samples.
“Our goal was to respond to current and future pandemics faster by removing the need for RNA extraction and the consumables required to process viral samples, which also has the added effect of increasing testing throughput,” said Dr. Bassam El-Fahmawi, Ph.D., chief executive officer and chief technical officer of Mawi DNA Technologies. “This product was also formulated to be non-toxic and non-hazardous by being free of guanidine salts while inactivating the virus, so our colleagues processing samples can conduct this invaluable service with peace of mind.”
Mawi DNA developed the new iSWAB-RC-EL collection device to address many of the inefficiencies in viral sample collection and transport technologies exposed during the COVID-19 pandemic, especially with cold chain transportation requirements and extremely short time frames for viral nucleic acid stabilization. The pandemic also exposed supply chain weaknesses, including shortages of RNA extraction reagents.
The iSWAB-RC-EL collection device is available immediately to hospital and clinical labs. To learn more about the iSWAB-RC-EL collection device or to request a sample, visit https://mawidna.com/request-sample-kit/.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi DNA’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi DNA, The Future of Biosampling is Here™. For more information, visit www.mawidna.com and follow the company on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005502/en/
Contact information
Investors
Jerome David, Chief of Staff
Mawi DNA Technologies
510-256-5186
j.david@mawidna.com
Media
Jessica Volchok
jessica@merrymancommunications.com
310-849-7985
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 14:00:00 EET | Press release
The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what looks likely to be a very busy annual meeting season.” Produced in association with White & Case, a global law firm, thereport reveals that while smaller-cap companies accounte
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues to advance with sonrotoclax, a potentially best-in-class BCL2 inhibitor that has demonstrated impressive clinical results, and our BTK CDAC BGB-16673, further strengthening our leadership in B cell malignancies, including CLL. With one of the most promising oncology pipelines in the industry, we are poised to deliver multiple data and regulatory milestones that wi
Shippeo Launches Shippeo AI, Turning Trusted Visibility Into Instant, Intelligent Action6.11.2025 13:00:00 EET | Press release
Shippeo, the leading provider of real-time transportation visibility (RTTV), revealed Shippeo AI today, at its Visibility Now! conference. This brand new intelligent layer of the Shippeo Platform delivers trusted visibility and instant action to empower the people behind global supply chains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106263715/en/ Alongside Shippeo AI, the company revealed a series of product enhancements: an all-new eCMR (Electronic Consignment Note) system; transformed Air Visibility; a deeper user experience for Finished Vehicle Logistics (FVL); and enhanced data accessibility and UX for the Shippeo platform. This raft of innovations reinforces Shippeo’s position as the world’s most trusted multimodal visibility platform. Shippeo AI, for people who keep the world moving… faster Shippeo AI, the new intelligent layer embedded across the entire Shippeo platform, transforms trusted visibility into con
Wireless Mobility Automotive becomes a 100% German-owned company strengthening its role as a trusted Western supplier6.11.2025 12:49:00 EET | Press release
Wireless Mobility, a leading provider of advanced cellular, automotive, smart and short-range modules, today announces that Wireless Mobility Automotive has become a wholly owned subsidiary of Wireless Mobility Holding GmbH, making the company a 100% German-owned enterprise. This milestone reinforces the company’s position as a transparent and independent Western supplier, fully aligned with the US connected vehicle ecosystem and addressing the expectations of global OEMs and tier one suppliers seeking reliable long-term partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021160513/en/ Norbert Muhrer, CEO, Wireless Mobility “This step underlines our clear commitment to transparency, independence and European quality,” said Norbert Muhrer, CEO of Wireless Mobility. “With German ownership, European engineering, and a global perspective, Wireless Mobility is ready to be the trusted Western supplier the industry has been
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 11:00:00 EET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom